Proteomic Markers of Alcohol Abuse (Phase 1)

描述(由申请人提供)：酒精依赖和酒精摄入的危险水平被低估和报告。在开发监测酒精使用水平和(或)近期饮酒的生物标记物(诊断)(状态标记物)和酒精依赖易感性标记物(特征、“病因学”标记物)方面付出了巨大努力。然而，这一研究领域尚未产生明确的工具，供治疗和预防专家和其他对此类信息感兴趣的人使用。 随着对人类基因组的详细了解，科学的新纪元出现了，人类蛋白质组现在正在被定义。蛋白质组学技术和信息学技术的力量已经准备好应用于寻找更好(更可靠)的诊断工具来诊断危险的酒精使用和酒精中毒。Lohocla Research Corporation可以从1000多名具有良好饮酒习惯、医疗/精神障碍、家族病史/精神障碍、药物使用等特征的人身上获得生物样本(血浆、血清和血小板)。Lohocla将与ProteoSep TM蛋白质组技术的开发商Eprogen合作，发现和测试一种新的酒精使用、滥用和酒精中毒诊断小组。 第一阶段研究将测试使用ProteoSep TM技术来识别和定量已知的因酒精摄入/酒精中毒而改变的蛋白质的可行性，并识别新的候选标记。我们将建立蛋白质组学方法(ProteoSep TM)，准确测量血浆和血清样本中目前使用的过度酒精摄入状态标记物(GGT、AST和CDT)，并利用ProteoSep TM技术开发一种测量血小板样本中MAO-B蛋白的方法。将应用一组生物信息学/统计工具来寻找新的标记。 如果我们能够成功地测量GGT、AST、CDT和MAO等蛋白质的水平，这些蛋白质将形成“内部标准”，其他新的标记蛋白可以在第二阶段进行测试。第一阶段的研究还将提供第一批候选标记，以便在第二阶段的更多受试者中进行评估。

DESCRIPTION (provided by applicant): Alcohol dependence and hazardous levels of ethanol ingestion are under-diagnosed and under-reported. Significant effort has been expended to develop biological markers (diagnostics) for monitoring levels and/or recency of alcohol use (state markers) and markers for predisposition to alcohol dependence (trait, "etiologic", markers). However, this area of research has not yet generated unequivocal tools to be used by treatment and prevention specialists and others interested in such information. A new era in science emerged with the detailed knowledge of the human genome and the human proteome is now being defined. The power of proteomic techniques and informatics technology is ready to be applied to the search for better (more reliable) diagnostic tools for hazardous alcohol use and alcoholism. Lohocla Research Corporation has access to biological samples (plasma, serum and platelets) from over 1,000 individuals who are well characterized with regards to drinking habits, medical/psychiatric disorders, family history of medical/psychiatric disorders, drug use, etc. Lohocla will partner with Eprogen, the developers of the ProteoSep TM proteomic technology, to discover and test a novel panel of diagnostics for alcohol use, abuse and alcoholism. Phase I studies, will test the feasibility of using ProteoSep TM technology to identify and quantitate proteins already known to be altered by alcohol intake/alcoholism and to identify novel candidate markers. We will establish proteomic methodology (ProteoSep TM) to accurately measure currently used state markers for excessive alcohol ingestion (GGT, AST and CDT) in plasma and serum samples and develop a measurement, with ProteoSep TM technology, of MAO-B protein in platelet samples. A panel of bioinformatic/statistical tools will be applied to search for new markers. If we are able to successfully measure the levels of proteins such as GGT, AST, CDT and MAO, these proteins will form "internal standards" against which other novel marker proteins can be tested in Phase II. Phase I studies will also provide the initial panel of candidate markers to be assessed in a significantly greater number of subjects in Phase ll.